IL6 and cancer: In the MBI post-intervention studies, most groups showed a mild-to-moderate decrease in IL-6 levels, with only the cancer group showing a moderate increase in IL-6 levels (SMD = 0.24; 95% CI, −0.29 to 0.76; Figure 2A).